Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 10, 2020
Daily News
February 10, 2020
- Drug Formularies Won’t Invade Doctors’ Rights to Prescribe: Payer Rep
February 10, 2020
- Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020
- Sumitomo Dainippon to Revise FY2022 Targets after Roivant Deal: President
February 10, 2020
- Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
- Chugai Joins NCC Scheme to Offer Free Drugs after Genomic Profiling
February 10, 2020
- After Erleada, Janssen Joins Hands with Nippon Shinyaku for Zytiga Too
February 10, 2020
- FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
February 10, 2020
- Stemirac Posts 130 Million Yen Sales in May-December: Nipro
February 10, 2020
- I’rom Teams Up with Shanghai Public Health Clinical Center to Tackle Novel Coronavirus
February 10, 2020
- Novo Nordisk’s Fiasp Ultra-Fast Acting Insulin Now Available in Japan
February 10, 2020
- Japan Ethical Drug Sales Up 3.7% in December 2019: Crecon
February 10, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…